Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Teva Pharmaceutical Industries
• Treatments: Rasagiline

Criteria

Inclusion Criteria:

• idiopathic Parkinson's disease.

• eligible to Azilect® treatment as per Canadian product monograph

Exclusion Criteria:

• exclusion (e.g. drug-drug interactions, contraindications, warnings and precautions) based on the Canadian product monograph.

• investigational drug within 30 days prior to study

• use of Azilect® or selegiline within 60 days prior to study

• significant medical condition